Latest Reimbursement News

Page 2 of 50
Pacific Edge has secured final Medicare coverage for Cxbladder Triage and Triage Plus in intermediate-risk microhematuria, with the policy due to take effect on 20 December. The decision gives the company a clearer reimbursement pathway, but revenue gains still depend on adoption and testing volumes.
Ada Torres
Ada Torres
6 Nov 2026
Aldoro has signed an MOU that would give WILLETECH a 51% stake in the Kameelburg project company and put the Namibian rare earths project on a proposed path to commercial production. The headline RMB2 billion funding commitment remains non-binding, however, with definitive agreements, approvals and proof of financing still outstanding.
Maxwell Dee
Maxwell Dee
5 Nov 2026
Edwards Lifesciences delivered stronger-than-expected third-quarter growth and lifted its full-year 2026 outlook, led by a sharp rise in mitral and tricuspid therapies. A US$220.2 million impairment charge remains a notable counterpoint to the upbeat operating performance.
Ada Torres
Ada Torres
5 Nov 2026
CVS Health plans to separate its healthcare solutions and retail pharmacy businesses by the first half of 2028, while raising its 2026 earnings and cash-flow targets. The announcement came alongside stronger third-quarter results, though management flagged elevated cost trends and potential macroeconomic pressure.
Ada Torres
Ada Torres
4 Nov 2026
Williams delivered higher third-quarter earnings and cash generation while keeping its 2026 guidance intact. The Momentum Midstream acquisition and a growing slate of pipeline, storage and power projects are now central to the company’s expansion case.
Maxwell Dee
Maxwell Dee
3 Nov 2026
Marriott delivered broad-based third-quarter growth and lifted its full-year RevPAR forecast, while expanding its hotel pipeline to a record 634,000-plus rooms. The result also combined stronger earnings with heavier debt and substantial share buybacks.
Victor Sage
Victor Sage
2 Nov 2026
Proteomics International has launched a discounted A$5 million share purchase plan as it moves from product development into commercial rollout. Eligible shareholders can buy shares at A$0.10 and may receive a free attaching option, subject to approval.
Ada Torres
Ada Torres
2 Nov 2026
LE Minerals finished FY2026 with a $48.17 million statutory profit, but the result was dominated by a one-off $58.14 million gain from selling its Solaroz lithium project interest. The company now has a substantial cash buffer to fund Queensland and Utah exploration while it seeks approval for a conditional $20 million graphite sale and spin-out.
Victor Sage
Victor Sage
2 Nov 2026
Adherium delivered a fifth consecutive quarterly record for remote patient monitoring revenue, but ended September with only A$120,000 in cash after a A$3.499 million operating outflow. Post-quarter loans and an AstraZeneca milestone payment have improved near-term liquidity, although further funding remains central to the company’s plans.
Victor Sage
Victor Sage
30 Oct 2026
LGP Cannatrek generated A$4.4 million in net operating cash flow on unaudited quarterly revenue of A$26.0 million, providing the first clean look at the merged group’s operations. Cost synergies, Danish production upgrades and UK expansion are advancing, while a pending TGA penalty remains an unresolved risk.
Ada Torres
Ada Torres
30 Oct 2026
Proteomics International has begun the national rollout of its Promarker D and Promarker Eso blood tests through Healius, while a A$2 million tax incentive receipt has lifted pro forma cash to A$3.8 million. Promarker Endo also cleared an independent Oxford validation hurdle, but its commercial launch remains conditional.
Ada Torres
Ada Torres
30 Oct 2026
Diatreme Resources has set out a sizeable economic case for its Northern Silica Project, with a pre-tax NPV of $1.29 billion for the base case and $2.419 billion if production expands. The catch is more immediate: the company held $1.9 million in corporate cash at quarter-end, equivalent to about 2.4 quarters of funding at its reported spending rate.
Maxwell Dee
Maxwell Dee
30 Oct 2026

Browse the archive

Full archive